COVID-19

What’s The Risk Of Myocarditis After mRNA-Based COVID-19 Vaccine?

The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged 16 to 17 years with 105.9 cases per million doses of the BNT162b2 vaccine.

Jama Network

What’s your Reaction?

LeftNeutralRight

What is the risk of myocarditis after mRNA-based COVID-19 vaccination in the US as calculated from the underreported VEARS system?

These rates appear to be a little low and I am unsure how they were able to divide myocarditis post vaccination in 12 to 15 year old boys by vaccination type in 12 to 15 year old boys.

Someone found a way to identify these people from people of all ages. Maybe genomics?

The rates of myocarditis cases were highest after the second vaccination dose in adolescent males aged:

— 16 to 17 years (105.9 per million doses of the BNT162b2 vaccine)

— 12 to 15 years old (70.7 per million doses of the BNT162b2 vaccine)

— 18 to 24 years (52.4 and 56.3 per million doses of the BNT162b2 vaccine and the mRNA-1273 vaccine, respectively)

Conclusion

Based on passive surveillance reporting in the US, the risk of myocarditis after receiving mRNA-based COVID-19 vaccines was increased across multiple age and sex strata and was highest after the second vaccination dose in adolescent males and young men.

What’s your Reaction?

LeftNeutralRight

Click to comment

Leave a Reply

Your email address will not be published.

To Top